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Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) may
occur after reconstructive or aesthetic breast surgery. Worldwide, approxi-
mately 1.7 million breast implant surgeries are performed each year. To
date, over 500 cases of BIA-ALCL have been reported around the world,
with 16 women having died. This review highlights the most important
facts surrounding BIA-ALCL. There is no consensus regarding the true inci-
dence rate of BIA-ALCL as it varies between countries, is probably
significantly under-reported and is difficult to estimate due to the true
number of breast prostheses used largely being unknown. BIA-ALCL devel-
ops in the breast mostly as a seroma surrounding the implant, but contained
within the fibrous capsule, or more rarely as a solid mass that can become
invasive infiltrating the chest wall and muscle, in some instances spreading
to adjacent lymph nodes, in these cases having a far worse prognosis. The
causation of BIA-ALCL remains to be established, but it has been proposed
that chronic infection and/or implant toxins may be involved. What is clear
is that complete capsulectomy is required for treatment of BIA-ALCL, which
for early-stage disease leads to cure, whereas chemotherapy is needed for
advanced-stage disease, whereby improved results have been reported
with the use of brentuximab. A worldwide database for BIA-ALCL and
implants should be supported by local governments.1. BIA-ALCL: an uncommon yet distinct disease entity
Breast implants have been the backbone of reconstructive and aesthetic breast
surgery for many years, and have had a significant impact on patients’ psycho-
logical well-being. Produced from apparently inert, non-toxic materials, breast
implants have largely been considered safe and relatively risk-free, although
concerns have been raised in the past [1–3]. However, a distinct group of lym-
phomas are increasingly being reported in association with breast implants.
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a
form of non-Hodgkin T-cell lymphoma (NHL) and presents as an accumulation
of T-lymphocytes, presenting as a late-onset seroma in one breast, with high
CD30 expression and an absence of anaplastic lymphoma kinase (ALK)
expression (figure 1). By contrast, non-implant-associated NHL found in the
breast are mostly B-cell lymphomas [4].
The first case of BIA-ALCL was reported in 1997 in association with implants
in a woman’s breast [5]. Since 1997, many case reports have been published in























Figure 1. The pathogenesis of BIA-ALCL is probably multifactorial but probably involves some form of chronic stimulus provided in either an antigen-dependent
( potentially via bacterial antigens) or antigen-independent manner (via cytokine stimulation and/or toxins activating the aryl hydrocarbon receptor) through which





(n ¼ 11) was published by Daphne de Jong, a pathologist at the
Netherlands Cancer Institute, Amsterdam [6]. In this series,
cases had been diagnosed between 1994 and 2006 in women
with a median age of 40 and all having surgery for cosmetic
reasons. However, it was not until 2011 that an official state-
ment from the US Food and Drug Administration (FDA) was
published. They reported on BIA-ALCL in the USA [7]. At
that time, the FDA had knowledge of 63 cases worldwide,
but with a total number of breast implant procedures world-
wide estimated at 5–10 million, the risk was deemed
extremely rare [8]. As such, in 2011, the FDA stated that ‘it
was not possible to confirm with statistical certainty that
breast implants cause ALCL’. Since 2011, awareness has
improved, although slowly, with more case series of BIA-
ALCL being reported, resulting in the provisional designation
of BIA-ALCL as a distinct clinical entity in the 2016 World
Health Organization (WHO) classification of lymphoid neo-
plasms, and the acceptance of a link between breast implants
and ALCL by the FDA 1 year later, with 414 Medical Device
Reports of BIA-ALCL and nine attributable deaths [9,10].
The FDA change in status on BIA-ALCL between 2011 and
2017 has been mediated by a number of BIA-ALCL series
reports from across the world. The first larger population-
based analysis from the Netherlands, published in 2008
described 389 women with breast lymphomas over a period
of 17 years (1990–2006; population of 8 million). Within this
series, 11 (3%) had histologically confirmed diagnoses of
ALCL, of which five were associated with breast implants
(5/11 ¼ 45%) [6]. The largest series published to date was of
173 histologically confirmed cases gleaned from the worldwide
literature demonstrating that every woman had received a tex-
tured implant as some point in their clinical history [11]. A later
review by Srinivasa et al. [11] investigated published incidences
of BIA-ALCL and found 363 reported cases including 258
entries in the U.S. Manufacturer and User Facility Device
Experience (MAUDE) database, although only 130 of these
were histologically confirmed as BIA-ALCL. More recently,
country-specific incidences have been published: 72 in Austra-
lia (of which three were lethal) [12], 41 cases in the UK [13,14],22 cases in Italy [15], 43 in the Netherlands [16], 19 in France [4],
seven cases in Germany [17] and 149 confirmed cases in the
USA (414 reported overall including nine deaths) [10,18].
However, all of these studies probably represent an unclear
estimation of actual incidence due to the number of unreported
breast implant surgeries and the incomplete recording of the
incidence of BIA-ALCL. Currently, the risk of a woman devel-
oping BIA-ALCL after undergoing implant-based surgery is
largely unknown, with reported incidences varying from
country to country. Various health experts such as the Ameri-
can Society of Plastic Surgeons, the MD Anderson Cancer
Center or the Australian Government Department of Health
state that based on currently available data, it is not possible
to provide an accurate estimate of risk. Current expert opinion
puts the risk of BIA-ALCL at 1 : 2832 for women with poly-
urethane implants in Australia and New Zealand, and
1 : 30 000 for women with any textured implant in the USA,
with the current UK risk estimated to be 1 : 24 000, a figure
based on all breast implants sold [13,18,19].
2. BIA-ALCL: diagnosis and therapy
ALCL can present as one of four types: systemic ALCL, which
is either ALK-positive (largely paediatric) or ALK-negative,
cutaneous ALCL, and the relatively recently described BIA-
ALCL [9,20,21]. All share some key features such as positivity
for CD30 expression but differ in prognosis and clinical
course. While largely indolent, BIA-ALCL may rarely be
aggressive and lead to death, as has been reported for
12 women so far [22,23]. In almost all reported cases, late-
onset seromas surrounding the breast implants (median 8
[1–36] years of inserting the breast implants) are seen, with
key symptoms including capsule thickening and capsular
contracture characteristically manifesting as unilateral breast
enlargement [22]. Late-onset seromas (greater than 1 year)
should be investigated by ultrasound of the breasts,
chest wall and regional lymph nodes. When ultrasound is
inconclusive, magnetic resonance imaging or computed tom-




3masses [24]. Ultrasound-guided aspiration of seroma fluid
with subsequent cytology, flow cytometry and analysis of
the cells, primarily for CD30 expression and negativity for
ALK helps to establish the diagnosis [25]. Patients may also
present with clinical symptoms such as dermatitis of the
breast and reactive enlarged axillary lymph nodes, in such
cases, excision biopsies followed by histopathological
analyses can aid in diagnosis [25].
Cases diagnosed as seroma are sometimes curable by sur-
gery alone (stage 1A; complete removal of the implant and
the surrounding fibrous capsule; a video of the removal of an
implant with BIA-ALCL can be seen at http://links.lww.
com/PRS/C360, although some also require adjuvant che-
motherapy (stage IIA) [22,26]. However, the best oncological
result can only be achieved by surgical treatment aiming for
complete surgical excision [26]. Radiotherapy is indicated
on occasions when there are positive margins on excision,
unresectable or residual disease [25]. If tumours are non-
resectable and have spread to the breast parenchyma, chest
wall and/or lymph nodes, chemotherapy is indicated [25].
At present, chemotherapy takes the form of the standard
T-cell lymphoma regimen, CHOP, with varying rates of
success [15]. The moderate amount of anecdotal data produced
so far suggests that event-free survival is far superior on treat-
ment with the anti-CD30 drug conjugate brentuximab, which
is unfortunately not available in all countries through National
Healthcare [27,28].3. Causes of BIA-ALCL
At present, the aetiology of BIA-ALCL is unclear, but the
consistent association of breast implants with this distinct
tumour entity lends some clues [20,29]. While considered
relatively inert, the full extent of potential in vivo toxicity
of implant materials, leachables and particulates is not
completely understood. In addition, while breast surgery is
considered a ‘clean contaminated site’, infection at the site of
the implant may be a contributing factor; indeed, some
other NHL are associated with chronic infection [30]. In
addition, clusters of women presenting with BIA-ALCL
have been reported consistent with an infectious aetiology
[19] . Finally, due to the rarity of this disease and the lack of
reported cases in some populations (such as Asian women),
there is likely to be a genetic element to this disease [11].
Breast implants have been through many iterations over the
years; at present, the fifth generation of implants are available,
designed with the intention of reducing the rate of capsular
contracture and preventing rotation, while providing an ana-
tomically pleasing shape [31,32]. Such features have been
provided by implants with textured surfaces, which are
attributable to the large majority of BIA-ALCL cases [19].
When comparing the number of textured implants involved
in BIA-ALCL diagnoses to the number of non-textured
implants, the former clearly make up the majority (table 1).
However, one must not forget that the type of implant
was known in only half of the reported cases, thus render-
ing interpretation of these data difficult. An FDA report
has identified 30 cases of BIA-ALCL associated with a
smooth implant surface (https://www.fda.gov/Medical
Devices/ProductsandMedicalProcedures/ImplantsandPros
thetics/BreastImplants/ucm481899.htm), but the clinical
histories for women are in some cases unknown with mostshown to have received a textured implant at some point in
the past. Indeed, a recent report from Australia and New Zeal-
and provided evidence that in 55 cases of BIA-ALCL, all
women had at some point a textured prosthesis implanted
[19]. There are differences in texture possibly leading to
different BIA-ALCL risk [19,35].
As the majority of cases are diagnosed in the context of a
textured implant, or history of a textured implant, this raises
the question as to the reasons for this association. Increased
T-cell infiltration in textured implants has been reported due
to bacteria-colonized biofilms enveloping the prosthesis, and
infections are associated with an elevated rate of seroma
formation and capsular contraction [36]. Chronic infection is
considered in some types of human lymphomas to be the
causing mechanism, and in many others a contributing pro-
cess [37]. It has, for instance, been known for a long time
that Helicobacter pylori is a leading cause for inflammation-
driven gastric cancer and mucosal-associated lymphoid
tissue (MALT) lymphoma [30]; antibiotic therapy can indeed
result in disease remission in some cases. Indeed, the role of
the microbiome in a number of cancers including breast,
oral, prostate and colorectal is becoming more apparent [38].
An infectious aetiology has not been reported for ALCL,
although a rare number of systemic ALCL have been attribu-
ted to insect bites [20,39,40]. Whether or not chronic infectious
agents/an inflammatory microenvironment drive the genetic
events in ALCL is also not known, although Ralstonia sp.
found in biofilms forming on the implant have been
implicated in BIA-ALCL [41]. Moreover, the co-expression of
CD30, a protein essential in the diagnosis of ALCL and nor-
mally found on activated T cells, further hints towards
activated T cells being the origin of this disease. Chronic,
T-lymphocyte-driven, but also fibroblast- and macrophage-
associated inflammation induces the formation of a capsule
that surrounds all implants. Whether the link between BIA-
ALCL and breast implants is due to bacterial infection
mediated by textured surfaces remains to be emphatically
shown, but Hu et al. showed a difference in the bacterial com-
position of the biofilm between involved and uninvolved
prostheses in women diagnosed with BIA-ALCL suggestive
of an association, although this study only examined three
patient’s implants in this regard [41]. In further evidence, by
adopting a peri-operative 14-point plan aiming to reduce
biofilm formation, eight experts succeeded in furnishing evi-
dence, through a retrospective analysis of their 21 000
patients with textured implants, that not a single case of
BIA-ALCL occurred after a median observation period of
11.7 years, although the methodologies used in this study
are debatable [19,42]. Hence, while there is no definitive
proof of an association between BIA-ALCL and infection,
the risk of infection should nevertheless be prevented as a
matter of good surgical practice. General proposals for a
reduction in the risk of infections caused by the implant,
and the above-mentioned 14-point plan have been presented
in this vein [36]. The latter consists essentially of peri-operative
and localized antibiotic treatment, short-time exposure of the
implant to air, the prevention of skin-implant contact and the
omission of any drainage tubes.
A large number of chemically active agents from metals to
vinyl derivatives and a number of aromatic hydrocarbons
including benzol and xylol have consequently been detected
in implant gels and exudates [43–45]. As it has been proven






















































































































































































































































































































































4ooze from the implants into the surrounding tissue, it is prob-
able that these tissues are also subject to infiltration by other
active agents in the gels [46]. Of these, the various detected
metals may directly induce oxidative stress and damage
DNA [47]. Moreover, cells in any tissue chronically exposed
to aromatic hydrocarbons may, due to the cytoplasmic
ligand-activated transcription factor, the aryl hydrocarbon
receptor (AHR), express several biotransforming cytochrome
P450 enzymes (CYP 1Aa/2 and 1B1), which in turn may pro-
duce mutagenic reactive species from the aromatics [48].
These species may also induce oxidative stress and DNA
damage. Breast cancer cells generally express high levels
of the AHR, which participate in a large number of endo-
genous and anti-tumour functions, and studies on human
and animals suggest that high AHR expression also concurs
with inflammatory conditions [49,50]. One other decisive
factor is that the AHR system, once activated by a number
of ligands, also plays a key role in the production of
inflammatory cytokines such as IL-17 [48]. Hence, AHR
expression is a useful marker for both the formation of reactive
species through CYP isoform-mediated biotransformation and
the inflammatory process in primary and malignant cells.
Whether the AHR is involved in BIA-ALCL pathogenesis
remains to be seen, but given that BIA-ALCL is considered a
malignancy of Th17/Th1 T-cell subsets, it is not improbable
[29,51–53]. While a Th1/Th17 origin has been proposed,
recent evidence is suggestive of a Th2 origin whereby eosino-
phils are seen in the involved capsules and tumour cells
express the transcription factor GATA3 and producing IL13
are observed [52]. These latter data are supportive of the
development of BIA-ALCL in the context of an allergic reaction.
Regardless of the mechanism(s) of disease pathogenesis,
both systemic ALCL and BIA-ALCL share common onco-
genic events; Jak1/STAT3 mutations are observed in
systemic ALCL, ALK2 and BIA-ALCL [54,55]. These pro-
teins are also key factors downstream of hyperactive ALK
activity in ALCL, ALKþ, which suggests that they play a cen-
tral role in ALCL [39,54–56]. However, alternative
mechanisms for constitutive activation of STAT3 cannot be
ruled out. The JAK/STAT3-targeted tyrosine kinase inhibitor
(e.g. sunitinib) may nevertheless be considered an interesting
strategy in the therapy of infiltrative BIA-ALCL. In contrast
with primary cutaneous ALCL and a subgroup of systemic
ALCL, ALK-associated with a favourable prognosis, there is
no indication as to a DUSP22 rearrangement in BIA-ALCL.
But in view of the small number of cases, further studies
are required to determine whether BIA-ALCL is a new gen-
etic subgroup of systemic ALCL, ALK2 or a part of the
still heterogeneous systemic ALCL, ALK2 entity or indeed
cutaneous ALCL due to its comparative indolent nature.4. Are breast implants associated with
other malignancies besides BIA-ALCL
and other rare lymphomas?
Some rare cases of lymphomas besides BIA-ALCL have been
reported in the context of breast implants, although whether
these are attributable to the implants or are coincidental
remains to be determined [57–61]. However, the risk of can-
cers, except lymphomas, developing due to breast implants
has not, to date, been verified in any study. In 2007, Brinton
royalsocietypublishing.org
5evaluated more than 13 000 women with breast implants and
demonstrated slightly higher rates of cervical, vulvar, gastric
and cerebral tumours, and leukaemias [62]. However, the
differences observed may be attributable to different lifestyles
between the two groups studied, rather than to breast
implants. By contrast, Singh et al. did not find any increase
in breast or other cancers, or any influence on systemic dis-
orders such as lupus or Sjogren’s syndrome upon analysis
of 55 000 patients receiving Allergan implants [63]./journal/rsob
Open
Biol.9:1900065. Discussion
BIA-ALCL has been described in the scientific literature since
1997 and is considered uncommon, albeit almost exclusively in
women with textured implants. To date, over 500 confirmed
cases and 16 deaths have been described worldwide [64].
There is no consensus regarding the true incidence rate of
BIA-ALCL as it varies worldwide and due to the high
number of undetected BIA-ALCL or under-reported use of
breast prostheses. Late-onset seroma and/or capsular contrac-
ture with unilateral breast swelling are some of the key
symptoms and should be further investigated for BIA-ALCL
by aspiration of seroma fluid with subsequent cytology, flow
cytometry and CD30 testing. Complete removal of implantsas well as the capsule is curative in the majority of cases, par-
ticularly those diagnosed at stage 1A. When infiltration of the
breast parenchyma, chest wall and/or lymph node involve-
ment is seen, the prognosis is negatively impacted and
adjuvant chemotherapy is required, particularly for non-
resectable disease. The aetiology of BIA-ALCL remains to be
determined but may be due to an infectious and/or toxic reac-
tion coupled with allergy or autoimmunity. Based on these
data, breast implants continue to be used in routine cosmetic
and reconstructive breast surgery. What is clear is that all
cases should be reported to their respective authorities and
women should be informed of the risks, no matter how
small, especially with regard to textured implants. It might
also be necessary to halt the use of textured implants until
more is understood about the pathogenesis of this disease
[42]. The introduction of obligatory worldwide BIA-ALCL
registers as well as reporting to the PROFLIE registry (www.
thepsf.org/PROFILE) should improve the collection of data.Data accessibility. This article has no additional data.
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